国际子宫移植学会注册研究第二次报告:2000-2024年全球活动
该研究基于国际子宫移植学会注册系统,分析了2000年4月6日至2024年12月31日期间全球24个中心记录的91例子宫移植。91例中67例来自活体供者,88%受者为Mayer-Rokitansky-Küster-Hauser综合征;12个月移植物存活率为75%,妊娠尝试共获44例健康单胎活产,每胚胎移植活产率30%。
要点
- 91例子宫移植中67例活体供者,12个月移植物存活率75%。
- 44例健康单胎活产,平均孕周34.5周,每胚胎移植活产率30%。
- 活产妊娠中子痫前期发生率为23%,11名婴儿发生重大产后并发症。
核心结论
- 子宫移植是绝对子宫因素不孕女性的唯一生育治疗,全球注册数据显示12个月移植物存活率75%,每胚胎移植活产率30%。
研究设计与样本
- 国际子宫移植学会网络注册系统数据分析,纳入2000年4月6日至2024年12月31日期间24个中心登记的91例子宫移植。
主要发现
- 91例移植中67例来自活体供者,24例来自 deceased 供者;88%受者患有Mayer-Rokitansky-Küster-Hauser综合征。
- 总体手术成功率(定义为12个月时移植物存活)为75%。
- 活体供者子宫切除术式包括开腹54%、机器人28%、腹腔镜18%。
- 活体供者移植的总缺血时间短于 deceased 供者移植。
- 排斥反应需升级免疫抑制治疗的比例在移植后1-5个月为44%,6-10个月为28%。
关键数值与推荐
- 12个月移植物存活率75%(总体手术成功率)。
- 每胚胎移植活产率30.3%(摘要总结)或30%(主要结果)。
- 活产平均孕周34.5周(摘要总结为35.3周,原文存在不一致)。
- 子痫前期在活产妊娠中发生率为23%。
临床怎么用
- 注册数据可用于子宫移植的质量评估和流程改进。
- 活体供者移植总缺血时间更短,绝经前供者移植物12个月存活率更优。
- 移植后1-5个月排斥反应需升级免疫抑制的比例较高,应加强监测。
局限性
- 注册数据为自我报告,未经审核验证。
- 至少四个中心的病例未录入注册系统而被排除。
- 部分持续病例尚未达到子宫切除终点,出生结局未知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What have been the activities, characteristics, and outcomes of uterus transplantation (UTx) performed worldwide from 2000 through 2024? SUMMARY ANSWER: In 91 UTx cases, 67 involved live donors and 80 of the recipients had Mayer-Rokitansky-Küster-Hauser syndrome, with 12-month graft survival of 74%, enabling pregnancy attempts that yielded 44 healthy singleton deliveries with a live birth rate per embryo transfer of 30.3%. WHAT IS KNOWN ALREADY: UTx is the only treatment for women with absolute uterine factor infertility who wish to carry a pregnancy. According to a comprehensive report including data up to 2020 on 45 UTx cases, 19 live births occurred (35.8% per embryo transfer) at a mean of 35.3 weeks gestation. STUDY DESIGN, SIZE, DURATION: Data were extracted from the web-based registry of the International Society of Uterus Transplantation (ISUTx). This registry captures information on donor and recipient characteristics, transplantation procedures, postoperative complications, immunosuppression, complications including rejections, and reproductive outcome. Analyses were undertaken of the 91 transplants performed between 6 April 2000 and 31 December 2024, that were recorded in the registry. PARTICIPANTS/MATERIALS, SETTING, METHODS: Twenty-four medical centers in five continents registered their uterus transplants by entering data from the day of transplantation until 3 months after graft removal. The following variables were assessed: the demographic and laboratory characteristics of donors and recipients, the source of graft (live versus deceased donor), surgical specifics including technique, duration, ischemic times, and post-op complications, immunosuppression, rejection data, pregnancy with live birth(s), and hysterectomy. MAIN RESULTS AND THE ROLE OF CHANCE: In 91 uterus transplantations (67 from live donors, 24 from deceased donors), the overall surgical success rate, defined as graft viability by 12 months, was 75%. Most recipients (88%) had Mayer-Rokitansky-Küster-Hauser syndrome, with mothers being the most frequent (64%) live donors. Live donor hysterectomies were performed by laparotomy (54%), robotics (28%), or laparoscopy (18%). Total ischemic time was shorter in live- versus deceased-donor UTx procedures. Rejection episodes that were treated with escalations of immunosuppression were more frequent during months 1-5 (44%) than during months 6-10 (28%) post-UTx. Graft survival during the first 12 months was superior when grafts from premenopausal donors were used as compared to from postmenopausal donors. Forty-four singleton live births (mean gestational length of 34.5 weeks), including eight second births, were reported, with a live birth rate per embryo transfer of 30%. Preeclampsia was the most common pregnancy complication, occurring in 23% of live-birth pregnancies. Major postnatal complications occurred in 11 infants, 9 with respiratory distress syndrome; no major malformations were observed. LIMITATIONS, REASONS FOR CAUTION: Data in the registry are self-reported and not subjected to validation. Although the ISUTx registry represents the most comprehensive quality registry of UTx activity in the world, cases from at least four centers are excluded as they were not entered into the registry. Birth outcomes from some registry cases are as yet unknown as these ongoing cases have not yet reached the endpoint of hysterectomy. WIDER IMPLICATIONS OF THE FINDINGS: This study presents the most comprehensive analysis to date of UTx, the only fertility treatment for absolute uterine factor infertility. The registry serves as the prime source for quality assessment and process improvement in UTx. STUDY FUNDING/COMPETING INTEREST(S): The establishment and operation of the registry were funded by the Swedish Research Council (2024-03487 to M.B.) and Jane and Dan Olsson Foundation (2024-11 to M.B.). There was no competing interest. TRIAL REGISTRATION NUMBER: Not applicable.
引用
- Brännström M, Racowsky C, Wiik J, et al. Second report of registry of the International Society of Uterus Transplantation (ISUTx): international activities 2000-2024. Hum Reprod. 2026. PMID: 41701557. doi:10.1093/humrep/deag017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。